Vironexis Biotherapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vironexis Biotherapeutics, founded in 2021, is developing a transformative platform for AAV-delivered T-cell immuno-gene therapy. The company's TransJoin™ platform is designed to create off-the-shelf, single-infusion therapies that engineer a patient's T cells in vivo to target and kill cancer cells, bypassing the need for complex ex vivo cell manufacturing. Its pipeline includes over ten preclinical programs targeting blood cancers, solid tumors, and cancer prevention, with its lead asset, VNX-101 for CD19+ leukemias and lymphomas, having received FDA IND clearance and multiple regulatory designations. The company is led by a founding team with deep expertise in gene therapy development and oncology.

OncologyAutoimmune Disorders

Technology Platform

TransJoin™ AAV Gene Therapy Platform: An off-the-shelf, single-dose AAV vector designed to deliver a transgene that programs a patient's T cells in vivo to express a bispecific molecule, redirecting them to kill tumor cells.

Opportunities

The company's off-the-shelf, single-dose platform addresses major cost and scalability limitations of current cell therapies, potentially capturing significant market share in multi-billion dollar oncology indications.

Successful proof-of-concept in its lead hematology program could de-risk the platform and unlock value across its broad pipeline in solid tumors and prevention.

Risk Factors

The novel in vivo AAV T-cell programming approach is unproven in humans and faces significant scientific risks, including immunogenicity, controlling T-cell specificity, and demonstrating efficacy in solid tumors.

The company is pre-revenue and will require substantial capital to advance its broad pipeline through clinical development.

Competitive Landscape

Vironexis competes in the crowded but rapidly evolving cancer immunotherapy space. Direct competitors include developers of allogeneic (off-the-shelf) CAR-T and CAR-NK cell therapies, as well as bispecific antibody platforms. Its key differentiation is the use of in vivo AAV gene delivery to create a persistent, engineered T-cell army, aiming for the potency of cell therapy with the simplicity of gene therapy.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →